IC50: Bruton kinase (BTK)[1]
BTK inhibitor 10 is a potent and orally active Bruton kinase (BTK) inhibitor, extracted from patent WO2018145525, example 33. BTK inhibitor 10 has a potential for rheumatoid arthritis treatment[1].
BTK inhibitor 10 (oral gavage; 30 mg/kg; 21 days; once daily) has a significant improvement in arthritis symptoms in CIA mice. The damage of each of the 4 paws in mice is divided into 0-4 to calculate the total score of the limbs. After 21 days' oral treatment, BTK030 reduces the arthritic score to 3.62 while the control group shows a value of 8.33[1].
| Animal Model: | DBA/1J mice injected with collagen as a CIA model[1] |
| Dosage: | 30 mg/kg |
| Administration: | oral gavage; 21 days; once daily |
| Result: | Decreased arthritis scores significantly when it compares to control group. |
[1]. HuiJun Yin, et al. Pyrrolo-aromatic heterocyclic compound, preparation method therefor, and medical use thereof. Patent WO2018145525